Vinorelbine therapy for Kaposi's sarcoma in a kidney transplant patient.
We report the case of a patient with Kaposi's sarcoma after kidney transplantation. Despite the discontinuation of azathioprine and a reduction in the cyclosporin dosage, the disease continued to evolve, and antineoplastic treatment became necessary. After 14 cycles of vinorelbine chemotherapy, there was a 75% regression of the initial lesions, despite the continuation of cyclosporin A.
Brambilla
L
L
Institute of Dermatology, University of Milan, IRCCS Ospedale Maggiore, Italy.
Boneschi
V
V
Fossati
S
S
Ferrucci
S
S
Finzi
A F
AF
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D016030:Kidney Transplantation / Q000009:adverse effects; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000556:secondary; D012878:Skin Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
D000972:Antineoplastic Agents, Phytogenic; D007166:Immunosuppressive Agents; D014747:Vinblastine; D016572:Cyclosporine; D001379:Azathioprine; D000077235:Vinorelbine